The plasma concentrations of pyridostigmine were measured in eight patients during the antagonism of non-depolarizing neuromuscular blockade. After the injection i. v. of pyridostigmine bromide 14.6 mg/70 kg, the concentration of the drug rapidly decreased between 2 and 7 min, and then declined more slowly. After 2 h, significant amounts of pyridostigmine were still present in the plasma of all subjects. In the eight patients studied, the initial half-life was 1.0 ±0.3 min and the terminal half-life was 46.4 ±6.5 min (mean ±SEM). Total body clearance of pyridostigmine was 8.7±1.5mlmin~1kg~1, and the total apparent volume of distribution was 536 ± 80 ml kg"'. Possible explanations for the differences between these results and previous studies arc considered.
Pyridostigmine bromide is used on occasions to antagonize non-depolarizing neuromuscular blockade, under which circumstances it has a longer duration of action than neostigmine (Miller et al., 1974) , although this is usually of little practical significance. Nevertheless, in certain circumstances, pyridostigmine may be preferable to neostigmine; in renal failure and after renal transplantation, pyridostigmine may decrease the possibility of recurarization, since its longer duration of action may counteract the prolonged effects of neuromuscular blocking drugs (Miller et al., 1974; Calvey and Wilson, 1980) . This paper is concerned with the plasma concentrations of pyridostigmine during the antagonism of neuromuscular blockade. Initial studies in man using equivalent doses of neostigmine and pyridostigmine showed that the clearance and volume of distribution of pyridostigmine were greater than those of neostigmine, although the elimination halflives of the two drugs were similar (Calvey et al., 1979; Calvey et al., 1981) . In the present paper, we have studied the kinetics, clearance and elimination of larger doses of pyridostigmine; doses which are similar in amount of drug to that sometimes used to antagonize the effects of non-depolarizing neuromuscular blocking drugs during clinical anaesthesia.
Eight patients (four male) were studied during plastic surgical procedures. The subjects were between 20 and 60 years of age and their body weights ranged from 50 to 87 kg. None had any clinical evidence of hepatic or renal disease, and the results of haematological and biochemical assessments (haemoglobin concentration and full blood count, and the concentrations of electrolytes, urea, creatinine, uric acid, inorganic phosphate, calcium, iron, bilirubin, albumin, globulin and aminotransferases) were within their physiological limits.
All the patients were premedicated with nitrazepam 10 mg orally, given on the previous night, and diazepam 5-10 mg orally on the day of operation. Following the induction of anaesthesia with thiopentone 200-400 mg, tubocurarine 45 mg was given. After tracheal intubation, anaesthesia was maintained with 60-70% nitrous oxide and 0.5% halothane in oxygen. Artificial ventilation of the lungs was used throughout. The duration of surgery was 60-90 min, and there was little or no fluid loss or replacement.
At the end of the operation, a polyethylene cannula attached to a three-way tap was placed in a superficial vein and kept patent by the infusion of small volumes of saline. Residual neuromuscular blockade was antagonized with pyridostigmine bromide 0.21 mg (800nmol) kg" 1 (14.6mg/70kg) and atropine sulphate 1.2 mg. Blood samples (approximately 8 ml) were removed at 2, 3, 4, 5, 7, 10, 15, 20, 40, 60, 80, 100, 120, 140, 160, 180 and 240 min, and added to lithium heparin. In all studies, plasma was removed from blood samples by centrifugation and stored at -20°C. Pyridostigmine was extracted from plasma as an iodide complex, and its concentration was determined by gas-liquid chromatography using a nitrogen detector (Chan et al., 1976) .
RESULTS
Pyridostigmine was rapidly eliminated from plasma during the antagonism of non-depolarizing blockade. The concentration of the drug decreased from 842±45ngmT 1 to 175±23ngml-' (mean±SEM) between 2 and 7 min, and then declined more slowly ( fig. 1) . After 2 h, significant amounts of pyridostigmine were still present in the plasma of all subjects, and the concentration of the drug was 37±7ngml~'. In six of the patients studied, pyridostigmine was not detected in plasma after 3 h; in one subject, trace amounts (about 1 ng ml" 1 ) were still present 4h after injection of the drug. Large inter-individual variations in the plasma concentration of pyridostigmine were not observed ( fig. 1 ) and the concentration of the drug was usually maintained within a relatively narrow range.
The relationship between the plasma concentration of pyridostigmine and time was invariably expressed as a biexponential equation of the form C P = Ae~" + Be'
9 ' using non-linear least squares regression analysis, where C P is the concentration of pyridostigmine in plasma at time t, and A, B, a and fJ are constants (table I) In the eight patients studied, pyridostigmine had an initial half-life of 0.3-2.5 min, and a terminal half-life of 17.1-72.7 min (table II). The total body clearance of the drug usually ranged from 4.8-8.3mlmin" 1 kg" 1 ; in two patients, greater values (13.0 ml min" 1 kg" 1 and 17.1 ml min" 1 kg" 1 ) were obtained. The total apparent volume of distribution ranged from 254 to 845 ml kg" 1 (table II) .
DISCUSSION
When pyridostigmine is used to antagonize nondepolarizing neuromuscular blockade, there are certain differences between its kinetics and those of neostigmine. The terminal half-life of pyridostigmine (46.4 ± 6.5 min) is longer than that of neostig- mine (25.5±2.7 min); its volume of distribution is 4-5 times greater and its clearance is 2-3 times more than neostigmine (Calvey et al., 1979) . Similar differences are present in experimental animals (Baker et al., 1978) . The longer half-life of pyridostigmine may explain the differences in the duration of action of the two drugs when they are used to antagonize non-depolarizing neuromuscular blockade (Miller et al., 1974) . Although the drugs are closely related chemically, in clinical practice neostigmine is more potent than pyridostigmine (by a factor of approximately 4:1). This presumably reflects the different affinities of their quaternary groups for the anionic site on acetylcholinesterase. Both neostigmine and pyridostigmine affect the enzyme in an identical manner; the esteratic site is modified by dimethylcarbamylation, and the halftime of recovery of the complex is approximately 30 min (Wilson, Harrison and Ginsburg, 1961; Kitz, 1964) . When pyridostigmine is used to reverse non-depolarizing blockade, its longer half-life may lead to significant re-carbamylation of the enzyme after its initial recovery, thus increasing the duration of action of the drug.
In the present experiments, the total body clearance of pyridostigmine was 8.7 ± 1.5 ml min"' kg"', or 609 ± 105 ml min" 1 in a 70-kg adult. These values are approximately twice the renal clearance of the drug in myasthenic patients taking pyridostigmine alone (334-481 ml min" 1 ) (Chan and Calvey, 1977) . Therefore, the results suggest that the clearance of pyridostigmine in man is almost equally dependent on metabolism (to 3-hydroxy-N-methylpyridinium) and on urinary elimination of the unchanged drug. There are important differences between our present results and previous studies concerned with the phannacokinetics of i.v. pyridostigmine in anaesthetized patients. In earlier studies, smaller doses of pyridostigmine were given during operation (Calvey et al., 1981) . In these situations, drug clearance was greater (16.3 ±1.6 ml mkr 1 kg" 1 ), but the total apparent volume of distribution was similar, resulting in a shorter terminal half-life (22.8 + 2.1 min). Other authors have infused much larger doses of pyridostigmine (equivalent to 35.3 mg pyridostigmine bromide per 70 kg) over a 2-min period during the antagonism of non-depolarizing blockade (Cronelly et al., 1980) . In patients with normal renal function, the initial and terminal half-lives of pyridostigmine were longer (6.8 ±0.4 min and 112 + 5 min respectively), and the steady-state volume of distribution (1.1+0.1 litre kg" 1 ) was greater than in the present study. Comparison with these results is difficult; there were considerable differences in experimental design and in the circumstances in which pyridostigmine was administered, and both general anaesthesia and surgery may have modified the kinetics of the drug. Alternatively, it is possible that the elimination of pyridostigmine is not dependent on first-order kinetics; this might account for the observed differences in the clearance and slow disposition half-life after varying doses of the drug. When oral pyridostigmine is used in the treatment of myasthenia gravis, the effects of highdose steroid therapy on the plasma concentration of the drug suggest that it may be eliminated by a saturable process (White, De Silva and Havard, 1981) . Although similar effects could occur when high doses of pyridostigmine are injected i.v., there is no definitive evidence to support this suggestion.
